Identification of apoptosis as key biochemical mechanism in nonalcoholic fatty liver disease after hepatic steatosis through bioinformatics and functional analyses

Zheng Liang; July Liang Chen

doi:10.62051/ijphmr.v1n1.07

Authors

Zheng Liang
July Liang Chen

DOI:

https://doi.org/10.62051/ijphmr.v1n1.07

Keywords:

NAFLD, Apoptosis, GEO, KEGG, GSEA

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) represents a growing global health crisis and is closely associated with increases in obesity and type 2 diabetes. Despite its ubiquity, its underlying biochemical mechanisms and effective therapeutic strategies remain poorly defined, hampering the development of targeted interventions.

Methods: Candidate genes were obtained from the GEO database, and Kyoto Encyclopedia of Genes and Genomes enrichment analysis and gene set enrichment analysis were used to identify pathways involved in NAFLD-related pathways. The top genes with higher degree in the protein-protein interaction network were crossed with the top genes enriched in key pathways, and then the correlation analysis between key genes and chemotherapy response was performed.

Result: Apoptosis, oxidative stress, NF-kB pathway, etc. are key pathways related to NAFLD. Lcn2, Mt1, Egr1, Jun, Nqo1, Btg2, Foxq1 and Hyou1 were enriched in key pathways of apoptosis.

Conclusion: Apoptosis, oxidative stress, NF-kB pathway are key pathways related to NAFLD.

References

M Fernandez, Lokan J, Leung C, et al. A critical evaluation of the role of iron overload in fatty liver disease [J]. J Gastroenterol Hepatol, 2022, 37(10): 1873-1883.

J-M Llovet, Willoughby C-E, Singal A-G, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment [J]. Nat Rev Gastroenterol Hepatol, 2023, 20(8): 487-503.

S-A Harrison, Allen A-M, Dubourg J, et al. Challenges and opportunities in NASH drug development [J]. Nat Med, 2023, 29(3): 562-573.

F Kanwal, Shubrook J-H, Younossi Z, et al. Preparing for the NASH Epidemic: A Call to Action [J]. Gastroenterology, 2021, 161(3): 1030-1042.

Z-M Younossi, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis [J]. J Hepatol, 2019, 71(4): 793-801.

O Verrastro, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial [J]. Lancet, 2023, 401(10390): 1786-1797.

H Ochi, Hirooka M, Koizumi Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases [J]. Hepatology, 2012, 56(4): 1271-1278.

T Kanda, Matsuoka S, Yamazaki M, et al. Apoptosis and non-alcoholic fatty liver diseases [J]. World J Gastroenterol, 2018, 24(25): 2661-2672.

J Chen, Li X, Ge C, et al. The multifaceted role of ferroptosis in liver disease [J]. Cell Death Differ, 2022, 29(3): 467-480.

C-D Byrne, Targher G. NAFLD: a multisystem disease [J]. J Hepatol, 2015, 62(1 Suppl): S47-S64.

A-R Saran, Dave S, Zarrinpar A. Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease [J]. Gastroenterology, 2020, 158(7): 1948-1966.

A Mukherji, Bailey S-M, Staels B, et al. The circadian clock and liver function in health and disease [J]. J Hepatol, 2019, 71(1): 200-211.

L Rui. Energy metabolism in the liver [J]. Compr Physiol, 2014, 4(1): 177-197.

H Reinke, Asher G. Circadian Clock Control of Liver Metabolic Functions [J]. Gastroenterology, 2016, 150(3): 574-580.

J Fang, Yu C-H, Li X-J, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications [J]. Front Cell Infect Microbiol, 2022, 12997018.

M Masoodi, Gastaldelli A, Hyotylainen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(12): 835-856.

M Trauner, Fuchs C-D. Novel therapeutic targets for cholestatic and fatty liver disease [J]. Gut, 2022, 71(1): 194-209.

K Pafili, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans [J]. Mol Metab, 2021, 50101122.

M Pawlak, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease [J]. J Hepatol, 2015, 62(3): 720-733.

E-E Canfora, Meex RCR, Venema K, et al. Gut microbial metabolites in obesity, NAFLD and T2DM [J]. Nat Rev Endocrinol, 2019, 15(5): 261-273.

J Heeren, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism [J]. Mol Metab, 2021, 50101238.

J Chen, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications [J]. Int J Mol Sci, 2020, 21(15).